Mouse DNAM-1/CD226 Antibody
R&D Systems, part of Bio-Techne | Catalog # AF4436
Key Product Details
Species Reactivity
Applications
Label
Antibody Source
Product Specifications
Immunogen
Glu19-Pro254
Accession # Q8K4F0
Specificity
Clonality
Host
Isotype
Applications for Mouse DNAM-1/CD226 Antibody
Western Blot
Sample: Recombinant Mouse DNAM-1/CD226 Fc Chimera (Catalog # 4436-DN)
Formulation, Preparation, and Storage
Purification
Reconstitution
Formulation
Shipping
Stability & Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: DNAM-1/CD226
DNAX accessory molecule-1 (DNAM-1), also known as CD226, is a 65 kDa type I transmembrane glycoprotein that belongs to the immunoglobulin superfamily (1). Mature mouse DNAM has a 236 amino acid (aa) extracellular domain (ECD) that contains two Ig-like C2-set domains, and possesses a 58 aa cytoplasmic region that contains motifs for binding PDZ domains and band 4.1 family proteins (1, 2). Within the ECD, mouse DNAM-1 shares 52% and 86% aa sequence identity with human and rat DNAM-1, respectively. Additional cDNA transcripts of mouse DNAM-1 may give rise to secreted or transmembrane isoforms with ECD deletions. DNAM-1 is expressed on several lymphoid and myeloid cell types and interacts with CD155/PVR and Nectin-2/CD112 (2‑4). Ligation of DNAM-1 promotes the activation of NK cells, CD8+ T cells, and mast cells (3‑7), induces dendritic cell maturation, initiates megakaryocyte and activated platelet adhesion to vascular endothelial cells, and stimulates monocyte extravasation; conversely, it inhibits the formation of osteoclasts (8‑11). Platelet-endothelium interactions that are mediated by DNAM-1 enable the metastasis of tumor cells to the lung (12). On activated, but not resting NK, T, and mast cells, the cis association of DNAM-1 with CD18 contributes to tyrosine and serine phosphorylation of DNAM-1 during activation (7, 10, 13‑15).
References
- Fuchs, A. and M. Colonna (2006) Semin. Cancer Biol. 16:359.
- Tahara-Hanaoka, S. et al. (2005) Biochem. Biophys. Res. Commun. 329:996.
- Bottino, C. et al. (2003) J. Exp. Med. 198:557.
- Tahara-Hanaoka, S. et al. (2004) Int. Immunol. 16:533.
- Shibuya, A. et al. (1996) Immunity 4:573.
- Dardalhon, V. et al. (2005) J. Immunol. 175:1558.
- Bachelet, I. et al. (2006) J. Biol. Chem. 281:27190.
- Reymond, N. et al. (2004) J. Exp. Med. 199:1331.
- Kakehi, S. et al. (2007) Mol. Cell. Biochem. 301:209.
- Kojima, H. et al. (2003) J. Biol. Chem. 278:36748.
- Tahara-Hanaoka, S. et al. (2006) Blood 107:1491.
- Morimoto, K. et al. (2007) Oncogene July 16 [Epub ahead of print].
- Shibuya, K. et al. (1999) Immunity 11:615.
- Shibuya, K. et al. (2003) J. Exp. Med. 198:1829.
- Shibuya, A. et al. (1998) J. Immunol. 166:1671.
Long Name
Alternate Names
Gene Symbol
UniProt
Additional DNAM-1/CD226 Products
Product Documents for Mouse DNAM-1/CD226 Antibody
Product Specific Notices for Mouse DNAM-1/CD226 Antibody
For research use only